An alternative topical treatment of osteoarthritis of the knee with cutaneous diclofenac solution

Bibliography

• Baert B, Deconinck E, Van Gele M, et al. Transdermal penetration behaviour of drugs: Cart-clustering, QSPR and selection of model compounds. Bioorg Med Chem 2007;15:6943-55
   PubMed Web of Science ®Google Scholar
• Moser K, Kriwet K, Naik A, et al. Passive skin penetration enhancement and its quantification in vitro. Eur J Pharm Biopharm 2001;52:103-12
   PubMed Web of Science ®Google Scholar
• Trommer H, Neubert RHH. Overcoming the stratum corneum: the modulation of skin penetration. Skin Pharmacol Physiol 2006;19:106-21
   PubMed Web of Science ®Google Scholar
• Grubauer G, Feingold KR, Harris RM, Elias PM. Lipid content and lipid type as determinants of the epidermal permeability barrier. J Lipid Res 1989;30:89-96
   PubMed Web of Science ®Google Scholar
• Potts RO, Francoeur ML. The influence of stratum corneum morphology on water permeability. J Invest Dermatol 1991;96:495-9
   PubMed Web of Science ®Google Scholar
• Elias PM. Epidermal lipids, barrier function, and desquamation. J Invest Dermatol 1983;80:44s-49s
   PubMedGoogle Scholar
• Wertz PW, Downing DT. Stratum corneum: biological and biochemical considerations. In: Hadgraft J, Guy RH, editors, Transdermal drug delivery: developmental issues and research initiatives. New York: Marcel Dekker; 1989
   Google Scholar
• Suhonen TM, Bouwstra JA, Urtti A. Chemical enhancement of percutaneous absorption in relation to stratum corneum structural alterations. J Control Release 1999;59:149-61
   PubMed Web of Science ®Google Scholar
• Nishihata T, Kamada A, Sakai K. Percutaneous absorption of diclofenac in rats and humans: aqueous gel formulation. Int J Pharm 1998;46:1-7
   Google Scholar
• Goosen C, du Plessis J, Müller DG, Janse van Rensburg LF. Correlation between physicochemical characteristics, pharmacokinetic properties and transdermal absorption of NSAID's. Int J Pharm 1998;163:203-9
   Web of Science ®Google Scholar
• Scheuplein RJ, Blank IH. Mechanism of percutaneous absorption. IV. Penetration of non-electrolytes (alcohols) from aqueous solution and from pure liquid. J Invest Dermatol 1973;60:286-96
   PubMed Web of Science ®Google Scholar
• Potts RO, Guy RH. Predicting skin permeability. Pharm Res 1992;9:663-9
   PubMed Web of Science ®Google Scholar
• Ho HO, Huang FC, Sokolaski TD, Sheu MT. The influence of cosolvents on the in vitro percutaneous penetration of diclofenac sodium from gel system. J Pharm Pharmacol 1994;46:636-42
   PubMed Web of Science ®Google Scholar
• Lopez A, Linares F, Cortell C, Herraes M. Comperative enhancer effects of Span® 20 with Tween® 20 and Azon® on the in vitro percutaneous penetration of compounds with different lipophilicities. Int J Pharm 2000;202:133-40
   PubMed Web of Science ®Google Scholar
• Kantarci G, Özgüney I, Karasulu HY, et al. Comparison of different water/oil microemulsions containing diclofenac sodium; preparation, characterization, release rate, and skin irritation studies. AAPS Pharm Sci Tech 2007;8(4):91
   PubMed Web of Science ®Google Scholar
• Watton PK, Mollgaard B, Hadgraft J, Hoelgaard A. Vehicle effect topical drug delivery. III. Effect of azon on the cutaneous permeation of metronidazol and propylene glycol. Int J Pharm 1985;24:19-26
   Google Scholar
• Lee PJ, Langer R, Shastri VP. Role of n-methyl pyrrolidone in the enhancement of aqueous phase transdermal transport. J Pharm Sci 2005;94:912-7
   PubMed Web of Science ®Google Scholar
• Fujii M, Bouno M, Fujita S, et al. Preparation of griseofulvin for topical application using N-methyl-2-pyrrolidone. Biol Pharm Bull 2000;23:1341-5
   PubMed Web of Science ®Google Scholar
• Kalbitz J, Neubert R, Wohlrab W. Modulation of drug penetration in the skin. Pharmazie 1996;51:619-37
   PubMed Web of Science ®Google Scholar
• Williams AC, Barry BW. Penetration enhancers. Adv Drug Deliv Rev 2004;56:603-18
   PubMed Web of Science ®Google Scholar
• Tashtoush BM, Al-Safi SA, Al-Fanek KJ. Azathioprine transport through rat skin and its immunosuppressive effect. Pharmazie 2004;59:143-6
   PubMed Web of Science ®Google Scholar
• Reddy LH, Ghosh B. Enhancer aided in vitro permeation of atenolol and prazosin hydrochloride through mice skin. Indian J Exp Biol 2001;39:47-51
   PubMedGoogle Scholar
• Myoung Y, Choi HK. Effects of vehicles and pressure sensitive adhesives on the penetration of isosorbide dinitrate across the hairless mouse skin. Drug Deliv 2002;9:121-6
   PubMed Web of Science ®Google Scholar
• Banerjee PK, Choudhury AK, Panja SK. Topical urea in dermatology. Indian J Dermatol 1990;35:17-24
   PubMedGoogle Scholar
• Lu MY, Lee D, Rao GS. Percutaneous absorption enhancement of leuprolide. Pharm Res 1992;9:1575-9
   PubMed Web of Science ®Google Scholar
• Vinod P, Shah VP, Maibach H. Topical drug bioavailability, bioequivalence and penetration. New York: Plenum Press; 1993
   Google Scholar
• Nishihata T, Kotera K, Nakano Y, Yamazaki M. Rat percutaneous transport of diclofenac and influence of hydrogenated soya phospholipids. Chem Pharm Bull 1987;35:3807-12
   PubMed Web of Science ®Google Scholar
• Yokomiza Y. Effect of phospholipids on the percutaneous penetration of drugs through the dorsal skin of the guinea pig, in vitro. Part 3. Effects of phospholipids on several drugs having different polarities. J Control Release 1996a;42:217-28
   Google Scholar
• Yokomiza Y. Effects of phospholipids on the percutaneous penetration of drugs through the dorsal skin of guinea pigs, in vitro and analysis of the molecular mechanism, using attenuated total reflectance-Fourier transform infrared (ATR-FTIR) spectroscopy. J Control Release 1996b;42:249-62
   Google Scholar
• Kirjavainen M, Monkkonen J, Saukkosaari M, et al. Phospholipids affect strateum corneum lipid bilayer fluidity and drug partitioning into the bilayers. J Control Release 1999a;29:207-14
   Google Scholar
• Touitou E, Junginger E, Weiner D, et al. Liposomes as carriers for topical and transdermal delivery. J Pharm Sci 1994;83:1189-203
   PubMed Web of Science ®Google Scholar
• Vyas SP, Singh R, Asati RK. Liposomally encapsulated diclofenac for sonophoresis induced systemic delivery. J Microencapsul 1995;12:149-54
   PubMed Web of Science ®Google Scholar
• Dayan N, Touitou E. Carriers for skin delivery of trihexyl phenidyl HCl: ethasomes versus liposomes. Biomaterials 2000;21:1879-85
   PubMed Web of Science ®Google Scholar
• Cevc G. Transfersomes, liposomes and other lipid suspensions on the skin:permeation enhancement of vesicle penetration, and transdermal drug delivery. Crit Rev Ther Drug Carrier Sys 1996;13:257-388
   PubMed Web of Science ®Google Scholar
• Thomas BJ, Finnin BC. The transdermal revolution. Drug Discov Today 2004;9:697-703
   PubMed Web of Science ®Google Scholar
• Kreilgaard M. Influence of microemulsions on cutaneous drug delivery. Adv Drug Deliv Rev 2002;54(Suppl 1):S77-S98
   PubMed Web of Science ®Google Scholar
• Lawrence RC, Helmick CG, Arnett FC, et al. Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum 1998;41:778-99
   PubMed Web of Science ®Google Scholar
• Felson DT, Lawrence RC, Dieppe PA, et al. Osteoarthritis: the disease and its prevalence and impact. In: Felson DT, conference chair. Osteoarthritis: new insights. Part I. The disease and its risk factors. Ann Intern Med 2000;133:635-46
   PubMed Web of Science ®Google Scholar
• Felson DT. Osteoarthritis, epidemiology of rheumatic diseases. Rheum Dis Clin North Am 1990;16:499-512
   PubMed Web of Science ®Google Scholar
• Grace D, Rogers J, Skeith K, Anderson K. Topical diclofenac versus placebo: a double blind, randomized clinical trial in patients with osteoarthritis of the knee. J Rheumatol 1999;26:2659-63
   PubMed Web of Science ®Google Scholar
• American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. Arthritis Rheum 2000;43:1905-15
   PubMed Web of Science ®Google Scholar
• Jordan KM, Arden NK, Doherty M, et al. EULAR recommendations 2003: an evidence based approach to the management of knee osteoarthritis: report of a task force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis 2003;62:1145-55
   PubMed Web of Science ®Google Scholar
• Creamer P, Hochberg MC. Osteoarthritis. Lancet 1997;350:503-8
   PubMed Web of Science ®Google Scholar
• Towheed TE, Hochberg MC. A systematic review of randomized controlled trials of pharmacological therapy in osteoarthritis of the hip. J Rheumatol 1997;24:349-57
   PubMed Web of Science ®Google Scholar
• Towheed TE, Hochberg MC. A systematic review of randomized controlled trials of pharmacological therapy in osteoarthritis of the knee, with an emphasis on trial methodology. Semin Arthritis Rheum 1997;26:755-70
   PubMedGoogle Scholar
• Towheed TE. Published meta-analyses of pharmacological therapies for osteoarthritis. Osteoarthritis Cartilage 2002;10:836-7
   PubMedGoogle Scholar
• Garner S, Fidan D, Frankish R, et al. Rofecoxib for rheumatoid arthritis. Cochrane Database Syst Rev 2005;CD003685
   Google Scholar
• Deviere J. Do selective cyclo-oxygenase inhibitors eliminate the adverse events associated with nonsteroidal anti-inflammatory drug therapy? Eur J Gastroenterol Hepatol 2002;14(Suppl 1):S29-33
   Google Scholar
• Wright JM. The double-edged sword of COX-2 selective NSAIDs. CMAJ 2002;167:1131-7
   PubMed Web of Science ®Google Scholar
• Towheed TE. Pennsaid® therapy for osteoarthritis of the knee: a systematic review and metaanalysis of randomized controlled trials. J Rheumatol 2006;33:567-73
   PubMed Web of Science ®Google Scholar
• Adeyeye CM, Li PK. Diclofenac sodium. In: Florey K, ed. Analytical Profiles of Drug Substances. New York: Academic Press; 1990
   Google Scholar
• Rubenstein JH, Laine L. Systematic review: the hepatotoxicity of non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther 2004;20:373-80
   PubMed Web of Science ®Google Scholar
• Helfgott SM, Sandberg-Cook J, Zakim D, et al. Diclofenac-associated hepatotoxicity. J Am Med Assoc 1990;264:2660-2
   PubMed Web of Science ®Google Scholar
• Sallie R. Diclofenac hepatitis. J Hepatol 1990;11:281
   PubMedGoogle Scholar
• Ouelette GS, Slitzky BE, Gates JA, et al. Reversible hepatitis associated with diclofenac. J Clin Gastroenterol 1991;13:205-10
   PubMedGoogle Scholar
• Purcell P, Henry D, Melville G. Diclofenac hepatitis. Gut 1991;32:1381-5
   PubMed Web of Science ®Google Scholar
• Ciccolunghi SN, Chaudri HA, Schubiger BI, et al. Report on a long term tolerability study of up to two years with diclofenac sodium (Voltaren). Scand J Rheumatol Suppl 1978;22:116-21
   Google Scholar
• Iveson TJ, Ryley NG, Kelly PMA, et al. Diclofenac associated hepatitis. J Hepatol 1990;10:85-9
   PubMed Web of Science ®Google Scholar
• Breen EG, McNicholl J, Cosgrove E, et al. Fatal hepatitis associated with diclofenac. Gut 1986;27:1390-3
   PubMed Web of Science ®Google Scholar
• Schapira D, Bassan L, Nahir AM, et al. Diclofenac-induced hepatotoxicity. Postgrad Med J 1986;62:63-5
   PubMed Web of Science ®Google Scholar
• Salama A, Gottsche B, Mueller-Eckhardt C. Autoantibodies and drug- or metabolite-dependent antibodies in patients with diclofenac immune haemolysis. Br J Haematol 1991;77:546-9
   PubMed Web of Science ®Google Scholar
• Scully LJ, Clarke D, Barr RJ. Diclofenac induced hepatitis: three cases with features of autoimmune chronic active hepatitis. Dig Dis Sci 1993;38:744-51
   PubMed Web of Science ®Google Scholar
• Bort R, Ponsoda X, Jover R, et al. Diclofenac toxicity to hepatocytes: a role for drug metabolism in cell toxicity. J Pharmacol Exp Ther 1999;288:65-72
   PubMed Web of Science ®Google Scholar
• Zheng WJ, Tang FL, Li J, et al. Efficacy and safety of diacerein in osteoarthritis of the knee: a randomized, multicenter, double-dummy, diclofenac-controlled trial in China. APLAR J Rheumatol 2006;9:64-9
   Google Scholar
• Moore RA. Topical NSAID are effective in osteoarthritis of the knee. J Rheumatol 2004;31:1893-5
   PubMedGoogle Scholar
• Evans JM, McMahon AD, McGilchrist MN, et al. Topical nonsteroidal anti-inflammatory drugs and admission to hospital for upper gastrointestinal bleeding and perforation: a record linkage case-control study. BMJ 1995;311:22-6
   PubMed Web of Science ®Google Scholar
• Heyneman CA, Lawless-Liday C, Wall GC. Oral versus topical NSAIDs in rheumatic diseases: a comparison. Drugs 2000;60:555-74
   PubMed Web of Science ®Google Scholar
• Moore RA, Tramer MR, Carroll D, et al. Quantitative systematic review of topically applied non-steroidal anti-inflammatory drugs [published correction appears in BMJ 1998;316:1059]. BMJ 1998;316:333-8
   PubMed Web of Science ®Google Scholar
• Rosenstein ED. Topical agents in the treatment of rheumatic disorders. Rheum Dis Clin North Am 1999;25:899-918, viii
   PubMed Web of Science ®Google Scholar
• Scott DL, Shipley M, Dawson A, et al. The clinical management of rheumatoid arthritis and osteoarthritis: strategies for improving clinical effectiveness. Br J Rheumatol 1998;37:546-54
   PubMedGoogle Scholar
• Singh P, Roberts MS. Skin permeability and local tissue concentrations of non-steroidal anti-inflammatory drugs after topical application. J Pharmacol Exp Ther 1994;268:144-51
   PubMed Web of Science ®Google Scholar
• Grahame R. Transdermal non-steroidal anti-inflammatory agents. Br J Clin Pract 1995;49:33-5
   PubMedGoogle Scholar
• Arellano A, Santoyo S, Martin C, Ygarta P. Enhancing effect of terpens on the in vitro percutaneous absorption of diclofenac sodium. Int J Pharm 1996;130:141-5
   Web of Science ®Google Scholar
• Reiss W, Sterlin H, Degen P, et al. Pharmacokinetics and metabolism of the anti-inflammatory agent voltaren. Scand J Rheumatol 1978;22:17-29
   Google Scholar
• Fowler PD. Voltarol: diclofenac sodium. Clin Rheum Dis 1979;5:427-64
   Google Scholar
• Fowler PD, Shadforth MF, Crook PR, John VA. Plasma and synovial fluid concentrations of diclofenac sodium and its major hydroxylated metabolites during long-term treatment of rheumatoid arthritis. Eur J Clin Pharmacol 1983;25:389-94
   PubMed Web of Science ®Google Scholar
• Roth SH, Shainhouse JZ. Efficacy and safety of a topical diclofenac solution (Pennsaid) in the treatment of primary osteoarthritis of the knee. A randomized, double-blind, vehicle controlled clinical trial. Arch Intern Med 2004;164:2017-23
   PubMed Web of Science ®Google Scholar
• Hewitt PG, Poblete N, Wester RC, et al. In vitro cutaneous disposition of a topical diclofenac lotion in human skin: effect of a multi-dose regimen. Pharm Res 1998;15:988-92
   PubMed Web of Science ®Google Scholar
• Özgüney (Sarigüllü) I, Karasulu HY, Kantarci G, et al. Transdermal delivery of diclofenac sodium through rat skin from various formulations. AAPS Pharm Sci Tech 2006;7(4):88
   PubMed Web of Science ®Google Scholar
• Kantarci G, Özgüney I, Karasulu HY, et al. In vitro permeation of diclofenac sodium from novel microemulsion formulations through rabbit skin. Drug Dev Res 2005;65:1-9
   Google Scholar
• Williams AC, Barry BW. Penetration enhancers. Adv Drug Deliv Rev 2004;56:603-18
   PubMed Web of Science ®Google Scholar
• Hui X, Hewitt PG, Poblete N, et al. In vivo bioavailability and metabolism of topical diclofenac lotion in human volunteers. Pharm Res 1998;15:1589-95
   PubMed Web of Science ®Google Scholar
• Tugwell PS, Wells GA, Shainhouse JZ. Equivalence study of a topical diclofenac solution (Pennsaid) compared with oral diclofenac in symptomatic treatment of osteoarthritis of the knee: a randomized controlled trial. J Rheumatol 2004;31:2002-12
   PubMed Web of Science ®Google Scholar
• McKenna F, Borenstein D, Wendt H, et al. Celecoxib versus diclofenac in the management of osteoarthritis of the knee. Scand J Rheumatol 2001;30:11-8
   PubMed Web of Science ®Google Scholar
• Maddrey WC, Maurath CJ, Verburg KM, Geis GS. The hepatic safety and tolerability of the novel cyclo-oxygenase-2 inhibitor celecoxib. Am J Ther 2000;7:153-8
   PubMedGoogle Scholar
• Bookman AM, Williams K, Shainhouse JZ. Effect of a topical diclofenac solution for relieving symptoms of primary osteoarthritis of the knee: a randomized controlled trial. CMAJ 2004;171:333-8
   PubMed Web of Science ®Google Scholar
• Yocum D, Fleischmann R, Dalgin P, et al. Safety and efficacy of meloxicam in the treatment of osteoarthritis. Arch Intern Med 2000;160:2947-54
   PubMed Web of Science ®Google Scholar
• Baer PA, Thomas LM, Shainhouse Z. Treatment of osteoarthritis of the knee with a topical diclofenac solution: a randomised controlled, 6-week trial [ISRCTN53366886]. BMC Musculoskelet Disord 2005;6(44):1-9
   PubMedGoogle Scholar